Last reviewed · How we verify
Higher-dose venlafaxine
Higher-dose venlafaxine is a Serotonin-norepinephrine reuptake inhibitor (SNRI) Small molecule drug developed by University of Pittsburgh. It is currently FDA-approved for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder. Also known as: Effexor.
Higher-dose venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability.
Venlafaxine is a small molecule serotonin transporter inhibitor, classified as an inhibitor and belonging to the drug class of serotonin transporter inhibitors. It has been studied for various conditions, including treatment-resistant depression, depression, depressive disorder, bipolar disorder, and obsessive-compulsive disorder, in clinical trials involving different dosages and comparisons to other medications.
At a glance
| Generic name | Higher-dose venlafaxine |
|---|---|
| Also known as | Effexor |
| Sponsor | University of Pittsburgh |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Target | Serotonin transporter (SERT), norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | FDA-approved |
Mechanism of action
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, thereby prolonging their action at neuronal synapses. At higher doses, it also exhibits weak dopamine reuptake inhibition. This mechanism is used to treat depression and anxiety disorders by restoring neurotransmitter balance.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Social anxiety disorder
- Panic disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Somnolence
- Sexual dysfunction
- Hypertension
- Sweating
Key clinical trials
- Multiple Ascending Dose Phase 1 Study of ALA-3000 (PHASE1)
- Pragmatic Trial of Obsessive-compulsive Disorder (PHASE2)
- Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder (PHASE2)
- ADAPT: Addressing Depression and Pain Together (PHASE4)
- Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene (PHASE4)
- Treatment of Obsessive Compulsive Disorder in Children (PHASE3)
- Optimizing Electroconvulsive Therapy for Depression (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Higher-dose venlafaxine CI brief — competitive landscape report
- Higher-dose venlafaxine updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI
Frequently asked questions about Higher-dose venlafaxine
What is Higher-dose venlafaxine?
How does Higher-dose venlafaxine work?
What is Higher-dose venlafaxine used for?
Who makes Higher-dose venlafaxine?
Is Higher-dose venlafaxine also known as anything else?
What drug class is Higher-dose venlafaxine in?
What development phase is Higher-dose venlafaxine in?
What are the side effects of Higher-dose venlafaxine?
What does Higher-dose venlafaxine target?
Related
- Drug class: All Serotonin-norepinephrine reuptake inhibitor (SNRI) drugs
- Target: All drugs targeting Serotonin transporter (SERT), norepinephrine transporter (NET)
- Manufacturer: University of Pittsburgh — full pipeline
- Therapeutic area: All drugs in Psychiatry/Mental Health
- Indication: Drugs for Major depressive disorder
- Indication: Drugs for Generalized anxiety disorder
- Indication: Drugs for Social anxiety disorder
- Also known as: Effexor
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing